{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 447995983
| IUPAC_name =  
| image =  
<!-- Clinical data -->
| tradename =  Euprotin, Granocyte, Lenobio, Neutrogin
| Drugs.com = {{drugs.com|international|lenograstim}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number =  135968-09-1
| ATC_prefix = L03
| ATC_suffix = AA10
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 6WS4C399GB
<!-- Chemical data -->
| chemical_formula =  
| molecular_weight =  
}}
'''Lenograstim''' is a [[Recombinant DNA|recombinant]] [[granulocyte colony-stimulating factor]] which functions as an [[immunostimulator]].<ref name="pmid1284891">{{cite journal | title = USAN Council. List No. 340. New names. Lenograstim | journal = Clin. Pharmacol. Ther. | volume = 52 | issue = 1 | pages = 113 |date=July 1992 | pmid = 1284891 | doi = 10.1038/clpt.1992.117 }}</ref><ref name="pmid15761020">{{cite journal |vauthors=Amadori S, Suciu S, Jehn U, Stasi R, Thomas X, Marie JP, Muus P, Lefrère F, Berneman Z, Fillet G, Denzlinger C, Willemze R, Leoni P, Leone G, Casini M, Ricciuti F, Vignetti M, Beeldens F, Mandelli F, De Witte T | title = Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study | journal = Blood | volume = 106 | issue = 1 | pages = 27–34 |date=July 2005 | pmid = 15761020 | pmc = 1895135 | doi = 10.1182/blood-2004-09-3728 }}</ref> It is developed  by [[Chugai Pharmaceutical Co.|Chugai Pharmaceuticals]] under the brand name '''Granocyte'''.

== References ==
{{Reflist}}


{{Immunostimulants}}
{{Cytokine receptor modulators}}
{{Growth factor receptor modulators}}

[[Category:Immunostimulants]]


{{antineoplastic-drug-stub}}

[[de:Lenograstim]]